There is increasing interest in using data from oral food challenges (OFC) performed under medical supervision to assist in allergy risk management, both in industry (allergen risk management) (1) and in the clinical management of the allergic individual (2). Data relating to the minimum eliciting dose (MED) needed to trigger symptoms can inform the need for precautionary allergen labelling (PAL) on food (1). However, given that ‘zero risk’ for food-allergic individuals is not considered to be a realistic proposition (3), it is also important to consider the severity of symptoms which might be experienced: for example, a pragmatic approach, using a level of exposure that causes only minimal, transient oral symptoms in under 1% of the food-allergic population, may be acceptable to guide the use of PAL (4). However, there is often an assumption that individuals with a lower MED (i.e. who react to a lower doses of allergen) are at a greater risk of anaphylaxis (5).

Much of this seems logical, although there are clearly limitations: we do not yet understand the inherent variability and reproducibility of an individual’s allergen threshold, although useful data will be generated by the TRACE Peanut Study (NCT01429896). The OFC scenario is very different from ‘real-life’ exposure: consumption of incremental doses of allergen at regular intervals (typically every 15–30 min) during OFC may induce a transient desensitizing effect leading to an overestimation of the MED (6). Moreover, OFC are usually terminated at the onset of objective and often mild symptoms for safety reasons. The literature indicates a median time for onset of severe symptoms following exposure to food allergen in the community of 10–30 min (7, 8); in contrast, using an extended dosing interval of 2 h, Blumchen et al. reported a median time to objective symptoms of 55 min (range 5–210 min) (9). Whether this disparity might also be due to a transient desensitizing effect with longer dosing intervals is unclear (10). For these reasons, a typical OFC regimen may overestimate MEDs, with many patients reacting to not the immediate preceding dose but a dose given 1–2 h beforehand.

**What is the relationship between dose of exposure and reaction severity?**

In much the same way that previous reactions do not predict the severity of future reactions (2), symptoms at in-hospital OFC do not reflect reactions occurring in the same individuals in the community (11), and vice versa (12). Presumably, this is due, at least in part, to the incremental dosing regimen used for OFC, allowing (at least in theory) for the challenge to be halted prior to onset of more severe symptoms. In contrast, allergic individuals consume (relatively) larger doses of allergen more rapidly in the community, before becoming aware of any symptoms. Therefore, the relationship between dose of exposure and resulting symptoms is unclear. One might expect a dose–response to exist (as is typical for most agonist/receptor interactions), with more severe symptoms being associated with higher levels of exposure. However, the data are seemingly contradictory: severe reactions at OFC have been reported at all levels of allergen exposure, down to milligram quantities (9, 13). Furthermore, data from OFC studies (which have not excluded individuals with prior anaphylaxis) suggest that individuals with prior anaphylaxis do not react to lower doses of allergen than those without (9, 12, 14, 15). The implication is that individuals who have previously reacted to very small levels of exposure are not more at risk of anaphylaxis, something which seems counterintuitive to clinical experience (16) and practice (5).

We (BKW) have previously reported a cohort of children who underwent OFC to peanut (17). In contrast to other studies, OFC were not terminated at onset of mild symptoms but allowed to progress. Twenty-seven children experienced positive reactions. Anaphylaxis was provoked in 21 (78%); in 13 cases, this was due to further allergen ingestion following initial mild symptoms. Of note, 6/27 children (22%) did not develop anaphylaxis despite completing the challenge (cumulative dose of 2.9 g peanut protein, equivalent to approximately 14 peanuts).

We have conducted a further analysis of this cohort, with reference to both the dose causing any symptoms versus that triggering anaphylaxis. We have also enriched the cohort with peanut-allergic children undergoing double-blind, placebo-controlled food challenges according to international consensus (10) as part of a desensitization study (BOPI study, NCT02149719), who also ingested further peanut following initial mild objective symptoms (which did not meet the stopping criteria for OFC). Children who did not experience objective symptoms were excluded from analysis. Both studies received local ethical approval, and written informed consent was obtained prior to OFC. The demographics of these cohorts are described in Table 1.

**We have identified 3 patterns of reactivity**

1. Those who experience nonanaphylactic symptoms despite consuming the top dose (Fig. 1). Whether these subjects...
would go on to experience anaphylaxis with further ‘supra-threshold’ allergen exposure beyond the 4–5 g protein dose recommended by international consensus (10) is unclear; at least one case report indicates this is a possibility (18).

2 Individuals who experience initially mild symptoms, but develop anaphylaxis with further exposure.

3 Allergic individuals who develop anaphylaxis as their initial symptom (often without preceding subjective symptoms), a phenomenon which can occur at all dosing levels.

We interpret these data as suggesting that individuals may have a threshold of reactivity for both any symptoms and a further threshold for symptoms of anaphylaxis (Fig. 2). In some, these two are very similar: such individuals will experience anaphylaxis as their initial symptom at OFC, with no apparent relationship between dose and severity. In others, there may be a significant difference between the two: in these subjects, a dose–severity relationship will be seen. However, at a group or population level, this relationship is diluted by individuals in the former category, and those who do not experience anaphylaxis due to the dose-limiting regimen used for OFC. Thus, while for most individuals it is likely a dose–severity relationship exists, this may not be seen at a population level.

What conclusions can be drawn from this model?

A major premise of OFC is the assumption that the procedure effectively dose-limits the risk of anaphylaxis. Our analysis implies that this probably holds true at an individual level, for most allergic individuals. It is important to consider how cofactors or augmenting factors (2, 19) may affect both the threshold/likelihood of any reaction, as well as the threshold triggering anaphylaxis. This clearly is difficult – to intentionally induce anaphylaxis presents both ethical and safety issues. Where the primary purpose of OFC is to determine the MED (rather than confirm clinical reactivity or assess response to immunomodulation), consideration must
be given to increasing the time interval in between doses. Fortunately, current attempts to use MEDs in improving allergen risk management mostly relate to ED01/ED05 levels (eliciting dose to provoke a reaction in 1% or 5% of the allergic population, respectively). This dosing level is generally equivalent to the first or second dose given during OFC, so overestimation of eliciting doses in the remaining 99%/95% of the population is unlikely to be a significant concern, something supported by the literature (20). Furthermore, low-dose, ‘single-dose’ challenge (at the ED05) levels are being used to further verify existing data (21).

The current PRACTALL recommendation for a seven- to eight-dose OFC protocol can be time-consuming in clinical practice. Clinicians may be tempted to use a lower number of doses in a lower risk, routine clinical setting where OFC are used to rule out clinical allergy (see example in Table 2). Such a protocol can result in some patients being given a higher dose than they might receive under a PRACTALL regimen, thus increasing the risk of more a severe reaction (a risk which might be greater if existing population dose distributions are overestimates).

Finally, the applicability of OFC data to inform the relationship between dose and severity in real-life community exposures will depend on the quality of the OFC protocol used, how representative the individuals challenged are to the wider allergic population (many historical studies excluded individuals with a history of anaphylaxis) and the completeness of the data set analysed. Despite a wealth of OFC data being reported in the literature, the quality of these data is not always apparent. In many cases, individual threshold data are not in the public domain; as a result, attempts to analyse the dose–severity relationship can be misleading. Zhu et al. analysed MEDs in the literature relating to individuals undergoing OFC and compared these to the severity of symptoms experienced. They reported that peanut-allergic individuals experiencing severe reactions had significantly higher MEDs than those with more mild reactions (22). However, many of the series analysed only reported MEDs for those with anaphylaxis or systemic reactions, and not for more mild reactions. As a result, over 40% of the MEDs reported in the source studies were not available for analysis. The resulting skewing of data, together with the likelihood that MEDs derived from OFC data for anaphylactic reactions may overestimate the true eliciting dose (for the reasons highlight above), almost certainly resulted in an unintended distortion of the available data.

Given the inherent risks of OFC, it is time that data relating to MEDs (particularly that arising from publicly-funded research) are made freely available through a data-sharing scheme, a scenario being proposed by leading medical journals (23). This would allow the community to better determine the relationship between dose and severity at OFC, and judge the applicability of this data to improve the management of allergic patients in the community.

Table 1 Patient characteristics

| Characteristic                              | Sydney Cohort | BOPI Cohort |
|---------------------------------------------|---------------|-------------|
| No. of patients included                    | 21            | 16          |
| Age at challenge (mean ± SD)                | 5.5 ± 3.7 years | 12.7 ± 2.5 years |
| SPT wheal size to commercial peanut extract (median, interquartile range) | 11 mm (6.5–15.5 mm) | 9 mm (6–23 mm) |
| Peanut-specific IgE (kUA/l)                 | 20.5 (0.86–100) | 33.9 (0.62–100) |
| IgE to rAra h 2 (kUA/l)                     | Not done      | 13.2 (0.21–100) |
| Gender, no. (%)                             |               |             |
| Male                                        | 17 (81)       | 10 (62)     |
| Female                                      | 4 (19)        | 6 (38)      |
| Other atopy, no. (%)                        |               |             |
| Asthma                                      | 7 (33)        | 13 (82)     |
| Allergic rhinitis                           | 7 (33)        | 14 (88)     |
| Eczema                                      | 13 (62)       | 7 (44)      |
| Other food allergy                          | 6 (29)        | 8 (50)      |
| Outcome of OFC no. (%)                      |               |             |
| Anaphylaxis                                 | 21 (100)      | 16 (100)    |
| As initial symptom                          | 3 (14)        | 2 (13)      |

SPT, skin prick test; OFC, oral food challenge.

Table 2 Typical OFC protocol for peanut according to PRACTALL Consensus (10), and how this compares to an abbreviated protocol derived from the available dose-distribution data (1)

| PRACTALL dosing (mg peanut protein) | Proportion of peanut-allergic population reacting to this level of exposure, % | Abbreviated protocol (mg peanut protein) |
|-------------------------------------|--------------------------------------------------------------------------------|----------------------------------------|
| 3                                   | ~8                                                                            | 10                                     |
| 10                                  | ~20                                                                           | 30                                     |
| 30                                  | ~30                                                                           | ~40                                    |
| 100                                 | ~50                                                                           | ~65                                    |
| 300                                 | ~65                                                                           | 300                                    |
| 1000                                | ~80                                                                           | 1000                                   |
| 3000                                | ~95                                                                           | 3000                                   |
News and commentaries

Funding

PJT is in receipt of a Clinician Scientist award funded by the UK Medical Research Council (reference MR/K010468/1) and is supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed are those of the author(s) and not necessarily those of the NHS, NIHR or the Department of Health. PJT is a member of an industry-sponsored ILSI expert group on predicting reaction severity.

Conflicts of interest

All authors declare no conflict of interest.

Author contributions

This article was co-written by PJT and BKW, who both approved the final version.

P. J. Turner1,2 and B. K. Wainstein3,4

1 Section of Paediatrics (Allergy and Infectious Diseases) & MRC and Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College London, London, UK;
2 Discipline of Child and Adolescent Health, Sydney Medical School, University of Sydney, Australia;
3 Department of Immunology and Infectious Diseases, Sydney Children’s Hospital, Sydney;
4 School of Women’s and Children’s Health, University of New South Wales, Sydney, NSW, Australia

Email: p.turner@imperial.ac.uk

References

1. Taylor SL, Baumert JL, Kruizenga AG, Remington BC, Crevel RW, Brooke-Taylor S et al. Establishment of reference doses for residues of allergenic foods: report of the VITAL expert panel. Food Chem Toxicol 2014;63:9–17.
2. Turner PJ, Baumert JL, Beyer K, Boyle R, Chan CH, Clark A et al. Can we identify patients at risk of life-threatening allergic reactions to food? Allergy 2016;71:1241–1255.
3. Madsen CB, Hattersley S, Allen KJ, Beyer K, Chan CH, Godefroy SB et al. Can we define a tolerable level of risk in food allergy? Report from a EuroPrevall/UK Food Standards Agency workshop. Clin Exp Allergy 2012;42:30–37.
4. DunnGalvin A, Chan CH, Crevel R, Grimson K, Poms R, Schnadt S et al. Precautionary allergen labelling: perspectives from key stakeholder groups. Allergy 2015;70:1039–1051.
5. Turner PJ, Skypala IJ, Fox AT. Advice provided by health professionals regarding precautionary allergen labelling. Pediatr Allergy Immunol 2014;25:290–292.
6. Niggemann B, Lange L, Finger A, Ziegert M, Müller V, Beyer K. Accurate oral food challenge requires a cumulative dose on a subsequent day. J Allergy Clin Immunol 2012;130:261–263.
7. Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 2000;30:1144–1150.
8. de Silva HL, Mehr SS, Tey D, Tang ML. Paediatric anaphylaxis: a 5 year retrospective review. Allergy 2008;63:1071–1076.
9. Blumchen K, Bedar A, Beschorner J, Ahrens F, Gruel A, Hamelmann E et al. Modified oral food challenge used with sensitization biomarkers provides more real-life clinical thresholds for peanut allergy. J Allergy Clin Immunol 2014;134:390–396.
10. Sampson HA, Gerth van Wijk R, Bindslev-Jensen C, Sicherer S, Teuber SS, Burks AW et al. Standardizing double-blind, placebo-controlled oral food challenges: American Academy of Allergy, Asthma & Immunology-European Academy of Allergy and Clinical Immunology PRACTALL consensus report. J Allergy Clin Immunol 2012;130:1260–1274.
11. Hourihane JO, Grimshaw KE, Lewis SA, Briggs RA, Trewin JB, King RM et al. Does severity of low-dose, double-blind, placebo-controlled food challenges reflect severity of allergic reactions to peanut in the community? Clin Exp Allergy 2005;35:1227–1233.
12. van Erp FC, Knulst AC, Kentie PA, Passmans SGM, van der Ent CK, Meijer Y. Can we predict severe reactions during peanut challenges in children? Pediatr Allergy Immunol 2013;24:596–602.
13. Rolinck-Werninghaus C, Niggemann B, Grabhenrich L, Wahn U, Beyer K. Outcome of oral food challenges in children in relation to symptom-eliciting allergen dose and allergen-specific IgE. Allergy 2012;67:951–957.
14. Taylor SL, Moneret-Vautrin DA, Crevel RW, Sheffield D, Morisset M, Dumont P et al. Threshold dose for peanut: risk characterization based upon diagnostic oral challenge of a series of 286 peanut-allergic individuals. Food Chem Toxicol 2010;48:814–819.
15. Eller E, Hansen TK, Bindslev-Jensen C. Clinical thresholds to egg, hazelnut, milk and peanut: results from a single-center study using standardized challenges. Ann Allergy Asthma Immunol 2012;108:332–336.
16. Wainstein BK, Saad RA. Repeat oral food challenges in peanut and tree nut allergic children with a history of mild/moderate reactions. Asia Pac Allergy 2015;5:170–176.
17. Wainstein BK, Studdert J, Ziegler M, Ziegler JB. Prediction of anaphylaxis during peanut food challenge: usefulness of the peanut skin prick test (SPT) and specific IgE level. Pediatr Allergy Immunol 2010;21:603–611.
18. Glaumann S, Nopp A, Johansson SG, Borres MP, Lilja G, Nilsson C. Anaphylaxis to peanuts in a 16-year-old girl with birch pollen allergy and with monosensitization to Ara h 8. J Allergy Clin Immunol Pract 2013;1:698–699.
19. Niggemann B, Beyer K. Factors augmenting allergic reactions. Allergy 2014;69:1582–1587.
20. Taylor SL, Houben GF, Baumert JL, Crevel RR, Allen KJ, Dubois AE et al. Understanding food allergen thresholds requires careful analysis of the available clinical data. J Allergy Clin Immunol 2015;135:583–584.
21. Zurzolo GA, Allen KJ, Taylor SL, Shreffler WG, Baumert JL, Tang ML et al. Peanut Allergen Threshold Study (PATS): validation of eliciting doses using a novel single-dose challenge protocol. Allergy Asthma Clin Immunol 2013;9:35.
22. Zhu J, Pou illot R, Kwegyr-Afful EK, Luccioi S, Gendel SM. A retrospective analysis of allergic reaction severities and minimal eliciting doses for peanut, milk, egg, and soy oral food challenges. Food Chem Toxicol 2015;80:92–100.
23. Tauchman DB, Backus J, Baethge C, Bauchner H, de Leeuw PW, Drazen JM et al. Sharing clinical trial data -a proposal from the international committee of medical journal editors. N Engl J Med 2016;374:384–386.